2014-03-14 08:55:01 - CURIS- Time to Assess Value Beyond Erivedge! - a new market research report on companiesandmarkets.com
Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis´s (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog pathway inhibitor) and CUDC-907 (PI3K/HDAC dual inhibitor, PhI) in PhI besides other products. BTK, PI3K and HDAC are clinically validated targets for treating leukemia´s.
Current SoC includes IV/SC mAbs (Rituxan/MabThera, Arzerra) in combinations with chemotherapy. There remains an unmet need for pts who are resistant or can not tolerate these treatment options. There are not too many unpartnered PI3K inhibitors in the pipeline and early promising data could trigger...
For more details, please read our report released on 11th February. 2013 on CRIS titled "Time
to Assess Value Beyond Erivedge!"
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.